Phase 3 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a consent form agreeing to take part in this extension study before it begins.
- People who previously took part in the SIRIUS-LN core study and completed the full treatment period up to Week 144, whether that was on the blinded or open-label treatment.
Who may not be able to join:
- People who have used certain therapies that are not permitted under this trial's rules (confirm with trial site for the specific list of prohibited treatments).
- Women who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cohort 1: Time to renal flare, increase in immunosuppressive medication, or death; Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.